natgillin/translations-raw huggingface dataset:
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26 August 2014 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 26 avgust 2014
These compounds can be absorbed in the blood. 
Te sestavine se lahko absorbirajo v kri.
Carcinogenicity studies were performed in mice and rats. 
Študije karcinogenosti so opravili na miših in podganah.
The serum phosphorus reduction was maintained over 55 weeks. 
Znižanje fosforja v serumu se je ohranilo več kot 55 tednov.
- Push the tablet through the aluminium foil. 
- Potisnite tableto skozi aluminijasto folijo.
The safety and efficacy of Velphoro in children and adolescents below the age of 18 years has not yet been established. 
Varnost in učinkovitost zdravila Velphoro pri otrocih in mladostnikih, starih manj kot 18 let, še nista bili dokazani.
Drug-drug interaction studies have only been performed in healthy volunteers. 
Študije medsebojnega delovanja med zdravili so bile opravljene samo pri zdravih prostovoljcih.
Blood levels of radiolabelled iron were very low and confined to the erythrocytes. 
Ravni radioaktivno označenega železa v krvi so bile zelo nizke in omejene na eritrocite.
See further information in section 4.4. 
Za več informacij glejte poglavje 4.4.
Vitamin D and 1,25-dihydroxy Vitamin D levels remained unchanged. 
Ravni vitamina D in 1,25­dihidroksi vitamina D so ostale nespremenjene.
There is no information on the effects of this medicine if taken during pregnancy or breastfeeding. 
Ni podatkov o učinkih tega zdravila, če ga jemljete v času nosečnosti ali dojenja.
Do not stop taking the medicine before talking to your doctor or pharmacist as the phosphorus level in your blood may increase (see section 1). 
Ne prenehajte jemati zdravila, dokler se ne posvetujete z zdravnikom ali s farmacevtom, saj se ravni fosforja v krvi lahko zvišajo (glejte poglavje 1).
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
• Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1
Tablets must be chewed and not swallowed whole; tablets may be crushed. 
Tablete je treba žvečiti in se jih ne sme pogoltniti celih; lahko se jih tudi zdrobi.
Only for the blister packs: - Separate the blister pack at perforations. 
Samo za pakiranja s pretisnimi omoti: - Ločite pretisni omot na perforacijah.
Maximum tolerated daily dose 
Največji dovoljen dnevni odmerek
Non-inferiority to sevelamer carbonate was determined at week 12. 
Neinferiornost sevelamerijevega karbonata je bila ugotovljena v 12. tednu.
The absolute absorption studies in humans were not performed. 
Študije absolutne absorpcije pri ljudeh niso bile izvedene.
In 2 Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose dependent effects were observed in healthy volunteers. 
V dveh študijah faze 1 so ugotovili, da je možnost za prenasičenost z železom minimalna in da pri zdravih prostovoljcih niso opazili učinkov, odvisnih od odmerka.
Component of a multipack. 
Del večjega pakiranja.
Therefore Velphoro is not recommended for use in children and adolescents. 
Zato zdravilo Velphoro ni priporočeno za uporabo pri otrocih in mladostnikih.
Of the total number of subjects in clinical studies of Velphoro, 29.7% were aged 65 and over, while 8.7% were aged 75 and over. 
Od skupnega števila bolnikov v kliničnih študijah zdravila Velphoro je bilo 29,7 % starih 65 let in več, medtem ko je bilo 8,7 % starih 75 let in več.
The reporting rate is classified as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100). 
Neželeni učinki so po stopnji poročanja razvrščeni kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100).
Description of selected adverse reactions *Diarrhoea 
Opis izbranih neželenih učinkov *Diareja
This medicine has no significant effect on your ability to drive or to use tools or machines. 
To zdravilo ne vpliva bistveno na sposobnost vožnje ali uporabe orodij oz. strojev.
This is thought to be most likely an adaptive response to the pharmacological effect of the drug, and not clinically relevant. 
Sklepajo, da je to najverjetneje prilagojevalni odziv na farmakološki učinek zdravila in ne šteje za klinično pomembnega.
Patients receiving Velphoro should adhere to their prescribed diets. 
Bolniki, ki jemljejo zdravilo Velphoro, se morajo držati svoje predpisane diete.
Subjects were continued on their study medication from week 12 to week 55. 
Preiskovanci so nadaljevali z jemanjem raziskovanega zdravila od 12. do 55. tedna.
The distribution studies in humans were not performed. 
Študije porazdelitve pri ljudeh niso bile izvedene.
After first opening of the bottle the chewable tablets can be used for 90 days. 
Po prvem odprtju plastenke lahko žvečljive tablete uporabljate še 90 dni.
The vast majority of these gastrointestinal disorders occurred early during treatment and abated with time with continued dosing. 
Do velike večine teh gastrointestinalnih težav je prišlo na začetku zdravljenja in so se z nadaljevanjem jemanja sčasoma zmanjšale.
Since absorption of iron from Velphoro is minimal (see section 5.2), excretion of iron from Velphoro in breast milk is unlikely. 
Ker je absorpcija železa iz zdravila Velphoro minimalna (glejte poglavje 5.2), je izločanje železa iz zdravila Velphoro v materino mleko malo verjetno.
Too much phosphorus in the blood can lead to calcium being deposited in tissues (calcification). 
Preveč fosforja v krvi lahko povzroči nalaganje kalcija v tkivih (kalcifikacija).
This study was an open-label, randomised, activecontrolled (sevelamer carbonate), parallel group study for up to 55 weeks. 
To je bila odprta, randomizirana, z učinkovino kontrolirana (sevelamerijev karbonat), vzporedna skupinska študija, ki je trajala do 55 tednov.
Clinical studies have demonstrated that the systemic absorption of iron from Velphoro is low. 
Klinične študije so pokazale, da je sistemska absorpcija železa iz zdravila Velphoro nizka.
In patients, absorbed iron is expected to be also distributed to the target organs, i.e. liver, spleen and bone marrow, and utilized by incorporation into red blood cells. 
Pri bolnikih je pričakovano, da se tudi absorbirano železo porazdeli v ciljne organe, tj. jetra, vranico in kostni mozeg, ter se porabi z vključitvijo v rdeče krvne celice.
If one or more doses are missed, the normal dose of the medicinal product should be resumed with the next meal. 
Če se izpusti enega ali več odmerkov, je z naslednjim obrokom treba vzeti običajni odmerek zdravila.
For any information about this medicine, please contact the Marketing Authorisation Holder. 
Za vse morebitne nadaljnje informacije o tem zdravilu se obrnite na predstavništvo imetnika dovoljenja za promet z zdravilom.
- Peel back the paper foil at the corner. 
- Odlepite folijo na vogalu.
In vitro studies with the following active substances did not show any relevant interaction: acetylsalicylic acid, cephalexin, cinacalcet, ciprofloxacin, clopidogrel, enalapril, hydrochlorothiazide, metformin, metoprolol, nifedipine, pioglitazone and quinidine. 
Študije in vitro z naslednjimi učinkovinami niso pokazale pomembnega medsebojnega delovanja: acetilsalicilna kislina, cefaleksin, cinakalcet, ciprofloksacin, klopidogrel, enalapril, hidroklorotiazid, metformin, metoprolol, nifedipin, pioglitazon in kinidin.
EU/1/14/943/002 90 chewable tablets 
EU/1/14/943/002 90 žvečljivih tablet
Table 1 Adverse reactions detected in clinical trials System Organ Class 
Tabela 1: Neželeni učinki, odkriti v kliničnih preskušanjih Organski sistem
Velphoro is almost not absorbed from the gastrointestinal tract. 
Zdravilo Velphoro se skoraj ne absorbira iz gastrointestinalnega trakta.
There was no clear evidence of a carcinogenic effect in mice. 
Pri miših ni bilo jasno opaznih karcinogenih učinkov.
Do not use this medicine after the expiry date stated on the carton, bottle or blister after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, plastenki ali pretisnem omotu poleg oznake »EXP«.
Diarrhoea occurred in 11.6% of patients in clinical trials. 
V kliničnih preskušanjih se je diareja pojavila pri 11,6 % bolnikov.
Due to the insolubility and degradation characteristics of Velphoro, no classical pharmacokinetic studies can be carried out, e.g., determination of the distribution volume, area under the curve, mean residence time, etc. 
Zaradi netopnosti in značilnosti razgradnje zdravila Velphoro ni mogoče izvesti klasičnih farmakokinetičnih študij, na primer določanja obsega porazdelitve, področja pod krivuljo, povprečnega časa prisotnosti itd.
Phosphate binding takes place by ligand exchange between hydroxyl groups and/or water and the phosphate ions throughout the physiological pH range of the gastrointestinal tract. 
Vezava fosfata poteka z izmenjavo liganda med hidroksilnimi skupinami in/ali vodo ter fosfatnimi ioni v celotnem fiziološkem razponu pH v gastrointestinalnem traktu.
92042 Paris la Défense Cedex France 
92042 Paris la Défense Cedex Francija
If you also have symptoms like increasing tiredness and breathlessness contact your doctor immediately (see section 2 “Warnings”). 
Če imate tudi druge simptome, kot je povečana utrujenost in zadihanost, se nemudoma obrnite na svojega zdravnika (glejte poglavje 2 »Opozorila«).
Patients with rare hereditary problems of fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoza­izomaltaze ne smejo jemati tega zdravila.
If you are pregnant or breastfeeding, or you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Do not take Velphoro: 
Ne jemljite zdravila Velphoro:
The European Medicines Agency has deferred the obligation to submit the results of studies with Velphoro in one or more subsets of the paediatric population in the treatment of hyperphosphataemia (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Velphoro za eno ali več podskupin pediatrične populacije pri zdravljenju hiperfosfatemije (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Effects seen in the rabbit embryo-foetal development toxicity study (skeletal variations and incomplete ossificaton) are related to exaggerated pharmacology, and likely not relevant for patients. 
Učinki, ki so jih opazili pri kuncih v toksikološki študiji razvoja zarodka/ploda (skeletne spremembe in nepopolna okostenelost), so povezani s pretirano farmakologijo in verjetno niso relevantni za bolnike.
In order to maximise the adsorption of dietary phosphate, the total daily dose should be divided across the meals of the day. 
Da bi povečali adsorpcijo prehranskega fosfata, je treba celotni dnevni odmerek razdeliti prek dnevnih obrokov.
- Take the tablet during a meal and chew it (if necessary, the tablet may be crushed to make this easier for you). 
- Tableto vzemite med obrokom in jo prežvečite (da vam bo lažje, jo lahko tudi zdrobite).
Pharmacotherapeutic group: Drugs for treatment of hyperkalaemia and hyperphosphataemia; ATC code: V03AE05 
Farmakoterapevtska skupina: zdravila za zdravljenje hiperkaliemije in hiperfosfatemije; oznaka ATC: V03AE05
- The amount of tablets taken per day should be divided across the meals of the day. 
- Količino tablet, ki jih morate vzeti na dan, porazdelite na dnevne obroke.
If you have missed a dose, just take the next dose at the usual time with a meal. 
Če ste pozabili vzeti odmerek, vzemite naslednji odmerek kot običajno z obrokom.
• Haemochromatosis and any other iron accumulation disorders. 
• Hemokromatoza in druge motnje kopičenja železa v telesu.
The current safety profile of Velphoro is based on a total of 778 patients on haemodialysis and 57 patients on peritoneal dialysis, who received Velphoro treatment of up to 55 weeks. 
Trenutni varnostni profil za zdravilo Velphoro temelji na skupno 778 bolnikih na hemodializi ter 57 bolnikih na peritonealni dializi, ki so 55 tednov v sklopu zdravljenja prejemali zdravilo Velphoro.
No special dose and administration guidelines were applied to seniors in these studies and the dosing schedules were not associated with any significant concerns. 
V teh študijah niso uporabljali nobenih posebnih smernic za odmerjanje in jemanje, pa tudi urnikom odmerjanja niso posvečali večjih skrbi.
Other reproduction toxicity studies showed no adverse effects. 
Druge študije vpliva na sposobnost razmnoževanja niso pokazale neželenih učinkov.
It may also lead to calcium deposits in soft tissues and bone causing effects such as red eyes, itchy skin and bone pain. 
Kalcij se lahko odlaga tudi v mehkih tkivih in kosteh, zaradi česar se lahko pojavijo znaki, kot so rdeče oči, srbeča koža in bolečine v kosteh.
- When taking Velphoro you should adhere to your recommended diet and treatments prescribed by your doctor such as calcium supplements, vitamin D3 or calcimimetics. 
- Če jemljete zdravilo Velphoro, morate upoštevati priporočeno dieto in zdravljenja, ki vam jih je predpisal zdravnik, na primer dodajanje kalcija, vitamina D3 ali kalcimimetikov.
In these clinical trials, approximately 43% of patients experienced at least one adverse reaction during Velphoro treatment, which were reported as serious adverse reactions in 0.36%. 
V teh kliničnih preskušanjih je med zdravljenjem z zdravilom Velphoro približno 43 % bolnikov doživelo najmanj en neželeni učinek, pri čemer je bilo 0,36 % resnih neželenih učinkov.
Concomitant administration of Velphoro did not affect the bioavailability of these medicinal products as measured by the area under the curve (AUC). 
Sočasno jemanje zdravila Velphoro ni vplivalo na biološko uporabnost teh zdravil, kot je bilo izmerjeno v področju pod krivuljo (AUC).
If you have black stools and also have symptoms like increasing tiredness and breathlessness contact your doctor immediately (see section 4). 
Če imate črno blato in tudi druge simptome, kot je povečana utrujenost in zadihanost, se nemudoma obrnite na svojega zdravnika (glejte poglavje 4).
This can result in stiffening of the blood vessels, making it harder for the blood to be pumped around the body. 
Zaradi tega lahko pride do otrdelosti krvnih žil, kar otežuje pretok krvi po telesu.
Can't be sold separately. 
Prodaja posameznega dela ni mogoča.
Your doctor may adjust the dose during the treatment course depending on the phosphorus level in your blood. 
Med zdravljenjem lahko odmerek prilagodi, odvisno od ravni fosforja v vaši krvi.
Any instances of overdose of Velphoro (e.g. hypophosphataemia) should be treated by standard clinical practice. 
Vse primere prevelikega odmerjanja zdravila Velphoro (npr. hipofosfatemijo) je treba zdraviti v skladu s standardno klinično prakso.
NAME OF THE MARKETING AUTHORISATION HOLDER Vifor Fresenius Medical Care Renal Pharma France 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Vifor Fresenius Medical Care Renal Pharma France
Non-clinical studies in several species (rats and dogs) showed that pn-FeOOH is distributed from the plasma to the liver, spleen and bone marrow, and utilized by incorporation into red blood cells. 
Neklinične študije pri več vrstah (podganah in psih) so pokazale, da se zdravilo Velphoro porazdeli iz plazme v jetra, vranico in kostni mozeg ter porabi z vključitvijo v rdeče krvne celice.
Tablets have a 20 mm diameter and a thickness of 6.5 mm. 
Tablete imajo premer 20 mm in debelino 6,5 mm.
They have been conducted in healthy human male and female subjects with losartan, furosemide, digoxin, warfarin, and omeprazole. 
Izvedli so jih na zdravih moških in ženskah, ki so jemali losartan, furosemid, digoksin, varfarin in omeprazol.
Velphoro may be harmful to the teeth. 
Zdravilo Velphoro lahko škodljivo vpliva na zobe.
90 chewable tablets 
90 žvečljivih tablet
- If you have any further questions, ask your doctor or pharmacist - This medicine has been prescribed for you only. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom - Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
This reduces the amount of phosphorus that can be absorbed into the bloodstream and thus lowers phosphorus levels in your blood. 
Tako se zmanjšuje količina fosforja, ki se lahko absorbira v krvni obtok, zaradi česar se znižajo ravni fosforja v krvi.
Hypercalcaemia Hypocalcaemia 
Hiperkalcemija Hipokalciemija
Reproductive and developmental toxicity studies in animals revealed no risk with respect to pregnancy, embryonic/foetal development, parturition or postnatal development (see section 5.3). 
Študije vpliva na sposobnost razmnoževanja in razvoja na živalih niso pokazale škodljivih učinkov na nosečnost, razvoj zarodka/ploda, porod ali postnatalni razvoj (glejte poglavje 5.3).
(rats and dogs) showed that systemic absorption was very low (≤1% of the administered dose). 
Neklinične študije pri več vrstah (podganah in psih) so pokazale, da je bila sistemska absorpcija zelo nizka (≤ 1 % danega odmerka).
Shelf-life after first opening the bottle: 90 days Opening date: 
Rok uporabnosti po prvem odprtju plastenke: 90 dni Datum odprtja:
What Velphoro is and what it is used for 
Kaj je zdravilo Velphoro in za kaj ga uporabljamo
The majority of the adverse reactions reported from trials were gastrointestinal disorders, with the most frequently reported adverse reactions being diarrhoea and discoloured faeces (very common). 
Večina neželenih učinkov, o katerih so poročali v preskušanjih, so bile gastrointestinalne težave, najpogostejši neželeni učinek pa sta bila diareja in sprememba barve blata (zelo pogosta).
Velphoro is a chewable tablet that must be taken with meals. 
Zdravilo Velphoro je žvečljiva tableta, ki jo je treba jemati s hrano.
Each tablet also contains 750 mg sucrose and 700 mg starches. 
Ena tableta vsebuje tudi 750 mg saharoze in 700 mg škroba.
Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease. 
Zdravilo Velphoro je treba uporabljati v okviru večstranskega terapevtskega pristopa, ki lahko vključuje jemanje dodatnega kalcija, 1,25­dihidroksi vitamina D3 ali katerega od njegovih analogov, ali kalcimimetikov za nadzor razvoja ledvične osteodistrofije.
METHOD AND ROUTE(S) OF ADMINISTRATION Tablets must be chewed or crushed and taken with meals. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Tablete je treba prežvečiti ali zdrobiti in jih jemati z obroki.
In clinical practice, treatment will be based on the need to control serum phosphorus levels, though patients who respond to Velphoro therapy usually achieve optimal serum phosphorus levels at doses of 1,500 - 2,000 mg iron per day (3 to 4 tablets). 
V klinični praksi bo zdravljenje odvisno od potrebe po nadzoru ravni fosforja v serumu, čeprav bolniki, ki se odzivajo na terapijo z zdravilom Velphoro, običajno dosežejo optimalne ravni fosforja v serumu pri odmerkih od 1500 do 2000 mg železa na dan (3 do 4 tablete).
If you are not sure, talk to your doctor before taking this medicine. 
Če niste prepričani, se pred jemanjem zdravila pogovorite s svojim zdravnikom.
Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or doseadjustment of either Velphoro or the concomitant medicinal product, or the physician should consider measuring blood levels. 
Čeprav se zdi možnost za medsebojno delovanje z drugimi zdravili majhna, je treba pri sočasnem zdravljenju z zdravili z ozko terapevtsko širino ob začetku jemanja ali prilagoditvi odmerka zdravila Velphoro ali zdravila, ki se jemlje sočasno, spremljati klinični učinek in neželene dogodke ali pa mora zdravnik preučiti smiselnost merjenja ravni v krvi.
The active moiety of Velphoro, pn-FeOOH, is practically insoluble and therefore not absorbed. 
Aktivna sestavina zdravila Velphoro, pn­FeOOH, je praktično netopna in se zato ne absorbira.
Peritonitis, gastric and hepatic disorders and gastrointestinal surgery Patients with a recent history of peritonitis (within the last 3 months), significant gastric or hepatic disorders and patients with major gastrointestinal surgery have not been included in clinical studies with Velphoro. 
Peritonitis, težave želodca in jeter ter gastrointestinalni kirurški poseg Bolniki z nedavno anamnezo peritonitisa (v zadnjih 3 mesecih), večjimi težavami želodca ali jeter in bolniki po zahtevnejšem gastrointestinalnem kirurškem posegu niso bili vključeni v klinične študije uporabe zdravila Velphoro.
What you need to know before you take Velphoro 
Kaj morate vedeti, preden boste vzeli zdravilo Velphoro
Talk to your doctor or pharmacist before taking Velphoro: - if you have had peritonitis, an inflammation of the peritoneum (the thin tissue that lines the inner wall of the abdomen) within the last 3 months, - if you have significant stomach and/or liver problems, - if you have had major surgery on your stomach and/or intestines. 
Pred začetkom jemanja zdravila Velphoro se posvetujte z zdravnikom ali farmacevtom: - če ste imeli v zadnjih 3 mesecih peritonitis, vnetje peritoneja (mehko tkivo, ki pokriva notranjo steno trebuha); - če imate hujše težave z želodcem in/ali jetri; - če ste imeli večji kirurški poseg na želodcu in/ali črevesju.
INFORMATION IN BRAILLE velphoro 
PODATKI V BRAILLOVI PISAVI velphoro
Uncommon (may affect up to 1 in 100 people): bloating (abdominal distension), inflammation of the stomach, abdominal discomfort, difficulty swallowing, acid coming back up from the stomach (gastrooesophageal reflux disease), tongue discolouration, low or high calcium levels in the blood seen in tests, tiredness, itch, rash, headache, shortness of breath. 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov): napihovanje (napenjanje), vnetje želodca, nelagodje v trebuhu, težave pri požiranju, kislina, ki se dviguje nazaj iz želodca (gastroezofagealna refluksna bolezen), razbarvanje jezika, nizka ali visoka raven kalcija v krvi, vidna na testih, utrujenost, srbečica, izpuščaj, glavobol, zasoplost.
In healthy subjects, the median uptake of radiolabelled iron in the blood was estimated to be 0.43% (range 0.16 - 1.25%) on Day 21, in pre-dialysis patients 0.06% (range 0.008 - 0.44%) and in haemodialysis patients 0.02% (range 0 - 0.04%). 
Pri zdravih preiskovancih je bil na 21. dan povprečen sprejem radioaktivno označenega železa v krvi ocenjen na 0,43 % (razpon 0,16 - 1,25 %), pri bolnikih pred dializo na 0,06 % (razpon 0,008 - 0,44 %) in pri bolnikih na hemodializi na 0,02 % (razpon 0 - 0,04 %).
In animal studies with rats and dogs administered 59Fe-Velphoro drug substance orally, radiolabelled iron was recovered in the faeces but not the urine. 
V študijah na živalih, kjer so podgane in psi peroralno dobivali učinkovino 59Fe­Velphoro, so odkrili radioaktivno označeno železo v blatu, ne pa tudi v urinu.
DO NOT swallow it whole. 
pogoltnite je cele.
The mean daily dose of Velphoro over 55 weeks of treatment was 1,650 mg iron and the mean daily dose of sevelamer carbonate was 6,960 mg. 
Povprečni dnevni odmerek zdravila Velphoro v 55 tednih zdravljenja je bil 1.650 mg železa in povprečni dnevni odmerek sevelamerijevega karbonata je bil 6.960 mg.
Data from clinical studies have shown that Velphoro does not affect the lipid lowering effects of HMG-CoA reductase inhibitors (e.g., atorvastatin and simvastatin). 
Podatki kliničnih študij kažejo, da zdravilo Velphoro ne vpliva na znižanje lipidov zaviralcev HMG­ CoA reduktaze (npr. atorvastatin in simvastatin).